As Founder/CEO/CFO, Eric has built eight biopharmaceutical, drug delivery and medical device companies. His success is based on the consistent theme of recognizing early breakthrough scientific concepts and their commercial applications. He has personally invested, developed, and executed profoundly impactful development, market, and growth strategies. Emerging from his experience is a tested, repeatable model for establishing the strategy, key resources, infrastructure, relationships, and financing to enable rapid commercialization, scaling, and growth. He has managed multiple products through clinical development, followed by 12 FDA marketing approvals or clearances. He has raised $138M from venture, angel, and family office sources, $101M from two IPOs, and $660M+ in strategic pharmaceutical company collaborations. Cumulative post-money valuations following financings exceeded $1.7B. Investor exits on six closed transactions averaged 8.3 times paid-in capital. Two companies reached annual revenues of $500+ and $800+ million under his tenure.
Eric was an original author of the National Childhood Injury Compensation Act, a no-fault alternative to the traditional tort system to provide compensation to people injured by certain pediatric vaccines. His initial financial risk-sharing models led to the creation of the Vaccine Manufacturers Assoc., teaming with Senators Arlen Spector and Ted Kennedy, and placing the necessary vaccine industry protections to enable capital investment, research, development and free broad-scale pediatric vaccine distribution to inner cities and rural America, including the primary solution to fulfill the National Vaccine Stockpile. Through 2022, over $5.2B in compensation has been paid out, and an industry now flourishes.
Over 35 years, he has co-initiated, driven and managed through full development and/or full global commercialization startup companies in behavioral healthcare (Atentiv – Sold); in pediatric, adult and traveler’s vaccines (Connaught Labs -IPO -now Sanofi-Pasteur, and Virogenetics-acquired); in combinatorial chemistry for drug discovery (ArQule – IPO – Merck acquired); in clinical genomics (Ardais – sold); in drug-delivery for endometriosis and PCOD (Combinent); in HDL/CHD therapeutics (Cardium – sold); and ADHD diagnostics (BioBehavioral Diagnostics – sold).
He began his career with Arthur Andersen & Co. in NYC specializing in M&A for pharmaceutical companies and then served as VP and CFO at Sterling Drug and General Manager at Glenbrook Labs.
Eric holds business degrees from Syracuse University, the University of Pennsylvania, The Wharton School and is a CPA.
